1. Impact of PSMA PET on Prostate Cancer Management
- Author
-
Weiner, Adam B, Agrawal, Raag, Valle, Luca F, Sonni, Ida, Kishan, Amar U, Rettig, Matthew B, Raman, Steven S, Calais, Jeremie, Boutros, Paul C, and Reiter, Robert E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Cancer ,Prostate Cancer ,Aging ,Urologic Diseases ,Biomedical Imaging ,Networking and Information Technology R&D (NITRD) ,Bioengineering ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Humans ,Male ,Antigens ,Surface ,Neoplasm Staging ,Positron Emission Tomography Computed Tomography ,Prospective Studies ,Prostatic Neoplasms ,Radiopharmaceuticals ,Prostate-Specific Antigen ,Clinical decision-making ,Drug therapy ,Neoplasm staging ,Positron-emission tomography ,Prognosis ,Prostatic neoplasms ,Radiotherapy ,Surgery ,Theranostic nanomedicine ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Opinion statementPSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.
- Published
- 2024